Boston Scientific Corp (BSX)vsCerus Corporation (CERS)
BSX
Boston Scientific Corp
$48.55
-0.55%
HEALTHCARE · Cap: $70.87B
CERS
Cerus Corporation
$2.71
-2.87%
HEALTHCARE · Cap: $559.03M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 9419% more annual revenue ($20.61B vs $216.56M). BSX leads profitability with a 17.3% profit margin vs -4.4%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
CERS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Intrinsic value data unavailable for CERS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 24.1% year-over-year
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -14.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : CERS
The strongest argument for CERS centers on Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : CERS
The primary concerns for CERS are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
BSX profiles as a mature stock while CERS is a growth play — different risk/reward profiles.
CERS carries more volatility with a beta of 1.77 — expect wider price swings.
CERS is growing revenue faster at 24.1% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 31/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Cerus Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?